Please login to the form below

Not currently logged in
Email:
Password:

AZ, BMS and Boehringer among UK Prix Galien finalists

They join Alexion, Chiesi, Janssen, Novartis, Otsuka and Takeda

Novartis awarded 2014 UK Prix Galien for Bexsero
Novartis awarded 2014 UK Prix Galien for Bexser

AstraZeneca, Bristol-Myers Squibb and Boehringer Ingelheim are among the finalists for the 2016 UK Prix Galien Awards.

The companies will line-up alongside Alexion, Chiesi, Janssen, Novartis, Otsuka and Takeda for a shot at one of the prestigious prizes later this year.

These will be awarded in just three categories - well-established innovative product, orphan product and the inaugural excellence in real world evidence.

Entry to the latter is only open to medicines that have previously won or received a commendation at the UK Prix Galien Awards, and this year Astellas, Celgene, MSD, Novartis and Sanofi Genzyme are in the running for the prize.

Karen Westaway, chief executive of ValueBase (new owners of Prix Galien's UK franchise), said: “We are particularly proud to become the first Prix Galien franchise to recognise excellence in real world evidence, which is becoming an increasingly important factor in the uptake of new innovations.

“This is an exciting new category and it will be fascinating to see how innovations that have previously impressed Prix Galien judges have fared in this crucial area.”

Westaway added: “The bottom line, however, is simple: the strong line-up of finalists - the biggest in the history of UK Prix Galien - is itself 'real world evidence' of the rich vein of innovation that runs through the UK pharmaceutical industry.”

The innovative and orphan product awards have been running since the UK Prix Galien was established in 1970, with the 2014 top places going to Bexsero, Novartis' breakthrough meningitis vaccine, and Janssen's Sirturo, the first tuberculosis medication to be approved in four decades.

Competing this year for the prestigious bi-annual medals are Alexion, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Chiesi, Janssen, Novartis, Otsuka and Takeda.

Innovative Product Award 2016 finalists

Generic NameBrand NameCompanyIndication (shortened)
vedolizumabEntyvioTakedaUlcerative Colitis and Crohn's Disease
sacubitril/ valsartanEntrestoNovartisSymptomatic chronic heart failure with reduced ejection fraction
ibrutinibImbruvicaJanssenMCL, CLL, WM
sebelipase alfaKanumaAlexioLysosomal acid lipase deficiency (LAL-D)
nivolumabOpdivoBMSMelanoma, lung cancer and renal cell carcinoma
idarucizumabPraxbindBoehringer IngelheimAnticoagulation reversal
osimertinibTagrissoAstraZenecaNon-small cell lung cancer (NSCLC)

Orphan Product Award 2016 finalists

Generic NameBrand NameCompanyIndication (shortened)
corneal epithelial cellsHoloclarChiesiEx vivo expanded autologous human corneal epithelial cells
tolvaptanJinarcOtsukaPolycystic kidney disease
nintedanibOfevBoehringer IngelheimIdiopathic pulmonary fibrosis
asfotase alfaStrensiqAlexionpaediatric-onset hypophosphatasia (HPP) - bone manifestations

Real World Evidence Award 2016 finalists

Generic NameBrand NameCompanyIndication (shortened)
fidaxomicinDificlirAstellasClostridium dificile infection
sitagliptinJanuviaMSDType 2 Diabetes Mellitus
alglucosidase alfaMyozymeSanofi GenzymePompe Disease
azacitidineVidazaCelgeneMyslodysplastic Syndrome
omalizumabXolairNovartisSever persistent allergic asthma

Article by
Rebecca Clifford

1st July 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....